2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  3. Antibody-Drug Conjugates (ADCs) EGFR
  4. Disitamab vedotin

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 2136633-23-1

Size Prix Stock Quantité
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtenir un devis  
100 mg   Obtenir un devis  

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Avis client

Based on 5 publication(s) in Google Scholar

Disitamab vedotin Related Antibodies

Top Publications Citing Use of Products

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900.  [Abstract]

    Disitamab vedotin (DV, 0.25 μg/mL) reduced the overall cell number of HER2-positive JIMT-1 breast cancer cells.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900.  [Abstract]

    Unlike the parental cells, which were sensitive to XMT-1522 and Disitamab vedotin (DV, 0.0001, 0.0006, 0.003, 0.016, 0.08, 0.4, 1, 2, and 10 μg/mL; 5 days), both D1 and D2 daughter cells that emerged from the DTP-PGCC were resistant to these drugs. D1, daughter-1 cells (one prior ADC treatment); D2, daughter-2 cells (two prior ADC treatments). ∗∗, p < 0.01; ∗∗∗, p < 0.001.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    Disitamab vedotin (DV, 50 μg/mL, 15 or 30 min) increased T-DM1 internalization into JIMT-1 breast cancer cells.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    In JIMT-1 xenografts, the combination of Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) plus T-DM1, as well as DV plus T-DXd, inhibited tumor growth more effectively than the corresponding single treatments.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    In macroscopic JIMT-1 xenografts, tumors that relapsed after T-DM1 treatment and subsequently responded to Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) but later progressed had lost HER2 expression. A: PBS; B: relapsed after T-DM1, progressed on T-DM1; C: relapsed after T-DM1, progressed on DV; D: relapsed after T-DM1, progressed on T-DXd.

    Voir tous les produits spécifiques à Isoform EGFR:

    Voir toutes les isoformes
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • Activité biologique

    • Pureté et documentation

    • Références

    • Avis client

    Description

    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity[1].

    IC50 & Target[1]

    HER2

     

    In Vitro

    The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Disitamab vedotin Related Antibodies
    Essai clinique
    Masse moléculaire

    149000 (average)

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    [Disitamab vedotin]
    Livraison

    Shipping with dry ice.
    Stockage

    -80°C, protect from light
    Pureté et documentation

    Purity: 98.90%

    SDS (251 KB)

    COA (232 KB) Others (223 KB) SEC-HPLC (77 KB)

    Instruction de manipulation (2659 KB)
    Références
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Disitamab vedotin Related Classifications

    • Calculateur de molarité

    • Calculateur de dilution

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Disitamab vedotin2136633-23-1RC48RC 48RC-48Antibody-Drug Conjugates (ADCs)EGFRAntibody-Drug ConjugatesEpidermal growth factor receptorErbB-1HER1anti-HER2antibodyMMAEantitumorimmunitygastriccancerbreastInhibitorinhibitorinhibit

    Vos produits récemment consultés:

    Demande en ligne

    Your information is safe with us. * Required Fields.

    Nom du produit

    		  

    Requested Quantity *

    Nom du demandeur *

    		 

    Civilité

    Adresse e-mail *

    		 

    Numéro de téléphone *

    Department

    		 

    Nom de l'organisation *

    City

    État

    Country or Region *

    		      

    Remarques

    Bulk Inquiry

    Inquiry Information

    Nom du produit:
    Disitamab vedotin
    Cat. No.:
    HY-P9985
    Quantité:
    MCE Japan Authorized Agent:

    Avis client

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nom du produit

    		  

    Lot #

    Nom du demandeur *

    		 

    Adresse e-mail *

    Numéro de téléphone

    		 

    Department *

    Nom de l'organisation *

    		 

    Country or Region *

    Remarques

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.